Find a Clinical Trial

Showing 221 - 230 of 234 Trials

  • A randomized, open-label, multicentric, two-arm pivotal trial of SonoCoud-9 combined with carboplatin (CBDCA) vs standard of care lomustine (CCNU) or temozolomide (TMZ) in patients undergoing planned resection for first recurrence glioblastoma

    Principal Investigator:

    Brian John Andrew Gill, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05902169

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to see if the implantable device, Sonocloud 9, is effective getting chemotherapy to better reach your tumor compared to receiving standard of care chemotherapy [Temozolomide and Lomustine] and to see how safe and tolerable the device is. Sonocloud 9 works by making the blood-brain barrier (BBB) more permeable(allowing liquids or gases to go through it) so chemotherapy can better reach your tumor. The BBB is a natural sealing of the blood vessels in the brain. This study is being done in participants whose brain tumor has returned and are eligible for surgery to...

  • Cluster Randomized Controlled Trial of Patient and Provider Decision Support to Increase Chemoprevention Informed Choice Among Women with Atypical Hyperplasia or Lobular Carcinoma In Situ - Making Informed Choices on Incorporating Chemoprevention Into

    Principal Investigator:

    Katherine D Crew, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04496739

    Population:

    Adult

    Phase:

    NA
    The study is being done to answer the following question: How can we best help women with atypical hyperplasia (AH) or lobular carcinoma in situ (LCIS) and their healthcare providers make informed decisions about whether to take breast cancer risk-reducing pills (drugs to slow or prevent breast cancer from developing)? Participants in this study will learn about their breast cancer risk, receive educational materials, and allow us to share their breast cancer risk information with their doctor. Are you Eligible? (Inclusion Criteria) Are you a woman between the ages of 35 and 74? Have you been...

  • DISRUPT: Aim 2

    Principal Investigator:

    Mary Beth Terry, PhD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT05146297

    Population:

    Adult

    Phase:

    NA
    That Black, Indigenous, and People of Color (BIPOC) are more likely to die from their cancer is well known. Despite years of progress in cancer research and treatment, most research is done in white populations. For this reason, it is not certain how best to treat BIPOC with cancer. The number of people with cancer who join a clinical trial (CT) in the United States at 8%. This low number is due to many reasons including the things related to the healthcare system, the number and type of clinical trials that are available, and the other illnesses patients have. These factors affect BIPOC...

  • Efficacy of a Pill-Dispensing System to Increase Disposal of Unused Opioids and to Reduce Refills after Cancer-Related Surgery

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    - Are you of 18 years or older? - Do you have upcoming open, non-laparoscopic surgery? - Is it planned that you will receive opioids in the post-operative period? - Are you able to download and use a iPhone or iPad application? Are you Eligible? (Inclusion Criteria) Are you of 18 years or older? Do you have upcoming open, non-laparoscopic surgery? Is it planned that you will receive opioids in the post-operative period? Are you able to download and use a iPhone or iPad application?

  • IMPACT Trial: Intervention to iMProve AdherenCe equitably

    Principal Investigator:

    Dawn L Hershman, MD, MS, FASCO

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    Many patients with breast cancer, who also take medicine to prevent heart disease such as a blood pressure medicine or a cholesterol medicine, experience frustration with the large number and difficult scheduling of their medications, known as “pill burden”. This study will help us find out how much “pill burden” exists in subjects with cancer at various stages, and how this intervention can help. Results of this study may help us figure out the best way to help patients manage their medications in the future. Are you Eligible? (Inclusion Criteria) Are you diagnosed...

  • Improving Medications Adherence Equitably among Patients with Metastatic Breast Cancerand Cardiovascular Disease

    Principal Investigator:

    Claire Marie Sathe, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to evaluate the effect of a multi-part intervention to reduce barriers to medication use. All subjects who are enrolled in the study will undergo the following interventions: 1) A complete medication reconciliation will be done where you will be asked about all current medication you have been prescribed. This is to create an accurate list of current medications you are taking. 2) A two-time visit with a pharmacist to review all the medicines you take, reasons for not taking medicines, and to create a personalized plan to help you take your medicines. After 4...

  • Nitrous Oxide For Endoscopic Ablation of Refractory Barrett’s Esophagus (NO FEAR-BE)

    Principal Investigator:

    Julian Adin Abrams, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03554356

    Population:

    Adult

    Phase:

    NA
    dy is to evaluate the safety and effectiveness of using the C2 CryoBalloon Focal Ablation System to treat any remaining Barrett’s Esophagus after receiving Radiofrequency Ablation (RFA). Are you Eligible? (Inclusion Criteria) Are you at least 18 years of age? Do you have a history of esophageal cancer? Are you willing to undergo an experimental treatment for your type of cancer?

  • Post-marketing surveillance of StrataCTX® flexible wound dressing for use as a steroid sparing agent

    Principal Investigator:

    Larisa J. Geskin, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT04087629

    Population:

    Adult

    Phase:

    NA
    To assess the use of StrataCTX® as a steroid sparing agent for disorders usually treated with topical steroids. Are you Eligible? (Inclusion Criteria) Age ≥ 18 years Ability to sign informed consent document Patient with a diagnosis of CTCL who have contact dermatitis to topical mechlorethamine gel Patients with a diagnosis of CTCL who have intractable pruritus Patients with a diagnosis of CTCL who rely heavily on topical steroids for symptomatic relief Patients on chemo/immunotherapy with drug induced rash Patients with cutaneous acute graft versus host disease

  • Pilot Study to Assess Feasibility, Acceptability, and Efficacy of a Food Navigation and Food DeliveryIntervention to Reduce Food Insecurity Among Patients with Metastatic Breast Cancer

    Principal Investigator:

    Claire Marie Sathe, MD

    Contact Number:

    212-342-5162

    Population:

    Adult

    Phase:

    NA
    The purpose of this research study to find out how we can best help patients with metastatic (advanced) breast cancer who sometimes worry not having enough food and provide resources to access the food that they need. We want to test an intervention by taking surveys to determine how it affects the patients, their food environment, and their mental health. Are you Eligible? (Inclusion Criteria) Must be 18 years old or older - Must have access to smartphone, tablet, or any type of telephone to complete surveys - Must be able to speak English or Spanish

  • RANDOMIZED NON-INFERIORITY TRIAL COMPARING OVERALL SURVIVAL OF PATIENTS MONITORED WITH SERUM TUMOR MARKER DIRECTED DISEASE MONITORING (STMDDM) VERSUS USUAL CARE IN PATIENTS WITH METASTATIC HORMONE RECEPTOR POSITIVE BREAST CANCER

    Principal Investigator:

    Melissa Accordino, MD

    Contact Number:

    212-342-5162

    NCT Number:

    NCT03723928

    Population:

    Adult

    Phase:

    NA
    The purpose of this study is to determine if overall survival of patients monitored with serum tumor marker direct disease monitoring (STMDDM) is as good as the overall survival of patients monitored with the usual care. Are you Eligible? (Inclusion Criteria) Do you have hormone positive, HER-2 negative, metastatic breast cancer? Are you 18 years of age or older? Are you willing to be monitored for your disease for the duration of this study?

Pages